Danaparoid Sodium (Orgaran®): An Update on its Approved Indications
Article Sidebar
Main Article Content
Abstract
Background: This review updates the rationale for danaparoid use and the clinical outcomes reported for its approved indications, while identifying areas in which its use may be optimized. Danaparoid, a low-molecular-weight heparinoid, is approved for deep-vein thrombosis prophylaxis and for the treatment of heparin-induced thrombocytopenia (HIT) and disseminated intravascular coagulation (DIC). It consists predominantly of heparan sulphate, of which a small fraction mediates anti-Xa activity through Antithrombin binding, whereas the larger fraction contributes importantly to thrombin generation inhibition and appears to modulate the actions of anti-PF4/polyanion antibodies and attenuate inflammatory responses. These features distinguish danaparoid from other approved antithrombotic agents.
Methods: From an extensive literature search covering 1981 to 2026, new publications, particularly from Japan, have been identified that extend our knowledge of danaparoid.
Results: Despite established dosing recommendations and a substantial body of efficacy and safety data, the clinical value of danaparoid may be underestimated because its pharmacologic behaviour is often misunderstood. This can lead to inappropriate dosing choices. In addition, contraindications and warnings may discourage danaparoid use in clinical settings in which it has shown value. In Japan, the intermittent dosing regimen approved there for DIC has been used unmodified for routine prophylaxis and thrombosis treatment with mixed results. Because of the complex pharmacokinetics of danaparoid, this regimen may be inappropriate in situations where continuous thrombotic and anti-inflammatory protection is required and also for routine thrombosis prophylaxis.
Conclusion: Adopting the established separate dosing recommendations for thrombosis treatment and prophylaxis could improve clinical outcomes. In particular, the therapeutic regime of an intravenous loading bolus followed by continuous therapeutic infusion may better sustain the interactions between danaparoid’s active components and thereby optimise its anticoagulant and immune-modulatory effects.
Article Details
Copyright (c) 2026 Magnani HN, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Gardini C, Urso E, Guerrini M C, Van Herpen R, De Wit P, Naggi A. Characterisation of danaparoid complex extractive drug by an orthogonal analytical approach. Molecules 2017;22:1116; Available from: https://dx.doi.org/10.3390/molecules 22071116AH.
Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992;22:58-65.
Ofosu F. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to Antithrombin III (Org 10849). Haemostasis 1992;22:66-72. Available from: https://doi.org/10.1159/000216297
Matsumoto S, Ohama R, Hoei T, Tojo R, Nakamura T. Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review. Cureus 2024;16(4):1-14. Available from: https://dx.doi.org/10.7759/cureus.58302.
Kottke-Marchant K, Duncan A. Antithrombin deficiency: Issues in laboratory diagnosis. Arch Pathol Lab Med 2002;126:1326–1336. Available from: https://doi.org/10.5858/2002-126-1326-ad
Hobbelen PMJ, Vogel GMT, Meuleman DG. Time courses of antithrombotic effects, bleeding enhancing effects and interactions with factor Xa and thrombin after administration of a low molecular weight heparinoid Org 10172 or heparin in rats. Thromb Res 1987;48:549-558. Available from: https://doi.org/10.1016/0049-3848(87)90386-0
Bourcy M, Pasalic L, Wang S, Campbell H, Liang HP, Chen V. Role for PARS and Thrombin-Gpibα Interaction for Thrombin Induced Procoagulant Platelet Formation. Blood 2017;130 Suppl 1:3607.
Bradbrook I, Magnani HN, Moelker HC, Morrison P, Robinson J, Rogers HJ,, et al. Org 10172 a low molecular weight heparinoid anticoagulant with a long half-life in man. B J Clin Pharmacol 1987;23(6): 667-75. Available from: https://doi.org/10.1111/j.1365-2125.1987.tb03100.x
Cate H, Henny ChP, ten Cate JW, Buller H, Mooy MC, Surachno S, Wilmink JM. Anticoagulant effect of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res 1985;38:211-22.
McCall F, Conkie JA, Walker ID, Davidson JF. Release of PF4 in vivo – comparison between heparin and a low molecular weight heparinoid (Org 10172). Presented to Br Soc Haemost Sept 1985
Peeters LL, Hobbelen PM, Verkeste CM, Vogel GM, Hassenack HG, Meuleman DG, et al. Placental transfer of Org 10172, a low molecular weight heparinoid in the awake late-pregnant guinea-pig. Thromb Res 1986;44/3:277-83. Available from: https://doi.org/10.1016/0049-3848(86)90002-2
Magnani HN. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran). Thromb Res 2010;125:297-302. Available from: https://doi.org/10.1016/j.thromres.2009.06.006
Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-Alternative anticoagulation in pregnancy and lactation. Sem Thromb Hemost 2002;28:439-446. Available from: https://doi.org/10.1055/s-2002-35284
Boer A, Kluft C, Dooijewaard G, Kasper FJ, Kroon JM, Breimer DD, Stiekema JC, Cohen AF. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thromb Haemost 1992;68(11):550-5.
He C, Wallen NH, Johnsson H, Blomback M. In vitro effects of argatroban, lepirudin and bivalirudin, and danaparoid on fibrin gel permeability. Semin Thromb Hemost 2008;34 Suppl 1:91-6.
He C, Blomback M, Bark N, Johnsson H, Wallen NH. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost 2010;108:1076-84. Available from: https://doi.org/10.1160/th09-05-0306
Dryjski M, Mikat E, Bjornsso TD. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid. J Vasc Surg 19888/5:623-33.
Seeds EA, Hanss J, Page CP. The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophil infiltration. J Lipid Mediators 1993, 7(3):269-278.
Harada N, Okajima K, Kochmura H, Uchiba M, Tomita T. Danaparoid sodium reduces ischaemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses. Thromb Haemost 2007; 79:81-7.
Hagiwara S, Iwasaka H, Hidaka S, Hishiyama S, Noguchi T. Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Crit Care 2008;12: R 43. Available from: https://doi.org/10.1186/cc6851
Hollenstein UM, Pernerstorfer T, Homoncik M, Hansen JB, Finzen H, Handler S, Jilma B. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infectious Dis. 2002;186(9):1270-6. Available from: https://doi.org/10.1086/344646
Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73(6):1592-6.
Greinacher A, Michels I, Mueller-Eckhardt C. Heparin associated thrombocytopenia: the antibody is not Heparin specific. Thromb Haemost 1992;67(5):545-9.
Krauel K, Furll B, Warkentin TE, Weitschies W, Kohlmann T, Sheppard I, Greinacher A. Heparin-induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-complexes. Thromb Haemost 2008;6:2160-7. Available from: https://doi.org/10.1111/j.1538-7836.2008.03171.x
Yasunaga K, Ogawa N, Mori K, Aoki N, Matsuda T, Nagakawa M, Kakishita E, Kuramoto A, Maruyama I. Evaluation of clinical effect of danaparoid sodium (KB-101) on disseminated intravascular coagulation (DIC). Jpn Pharmacol Ther 1995;23:2815-34. Japanese.
Fujishima Y, Yokota K, Miyake Y, Sukamoto T. The effects of the low molecular weight heparinoid danaparoid sodium and its fractions on endotoxin-induced experimental disseminated intravascular coagulation. Jpn J Pharmacol 1998;79:177P. Japanese.
Iba T, Kidokoro A., Fukunaga M, Nagakari K, Suda M, Yoshikawa S, et al. Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intens Care Med 2005;31:1101-8. Available from: https://doi.org/10.1007/s00134-005-2707-0
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020,120(7):1004-1024. Available from: https://doi.org/10.1055/s-0040-1713152
Magnani HN. Rationale for the role of heparin and related GAG antithrombotics in COVID-19 infection. Clin Appl Thromb Hemost 2020;27:1-26. Available from: https://dx.doi.org/10.1177/1076029620977702.
Danhof M, De Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992;22:73-84. https://doi.org/10.1159/000216298
Cade JF, Wood M, Magnani H, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in prevention of venous thrombosis. Thromb Res 1987;45:479-503.
Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, et al. Low molecular weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996;93:80-84. Available from: https://doi.org/10.1161/01.cir.93.1.80
Yasunaga K, et al. PK in healthy volunteers. Jpn Pharmacol Ther 1995;23/5:1345-1374.
Nakano J, Tsbouchi H, Iida Y, Takayanagi T, Yamazaki J, Mabuchi N,, et al. Pharmacokinetics of danaparoid sodium in patients undergoing continuous haemodiafiltration complicated by disseminated intravascular coagulation. J Jpn Soc Intens Care Med 2009;16:67-70. Japanese.
Frei U, Wilkes MF, Boehmer S, Crisp-Lindgren M, et al. Gastro-intestinal blood loss in haemodialysis patients during the use of a low molecular weight heparinoid anticoagulant. Nephrol Dial Transplant 1988;3:435-9.
Hoppensteadt D, Fareed J, Walenga JM, Iqbal O. Relative contribution of the high and low AT-III affinity components of a heparinoid (Lomoparan) in the mediation of antiprotease, anticoagulant and antithrombotic actions. Thromb Haemost 1991;65(6):1297Abstr 2180.
Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. B J Pharmacol. 2005;146(3):333-43. Available from: https://dx.doi.org/10.1038/sj.bjp.0706344.
Horn P, Bueltmann E, Buch CV, Schmiedek P. Arterio-embolic ischemic stroke in children with moyamoya disease. Childs Nervous Syst 2005;21(2):104-7. Available from: https://doi.org/10.1007/s00381-004-0962-y
Magnani H, Wester J. Orgaran® use in intensive care unit patients with heparin-induced thrombocytopenia and acute renal failure. Crit Care 2007;11/2: S 149 abstract P371. Available from: https://doi.org/10.1186/cc5531
Lindhoff-Last E, Betz C, Bauersachs R. Use of a low molecular weight heparinoid (Danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001;7:300-4. Available from: https://doi.org/10.1177/107602960100700409
Magnani HN. A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis. Thromb Res 2005;125:e171-6. Available from: https://doi.org/10.1016/j.thromres.2009.10.008
Magnani HN, Beijering RJR, ten Cate JW. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In Pifarre R editor. New Anticoagulants for the Cardiovascular Patient. Hanley & Belfus, Philadelphia; 1997. p. 487–500.
Olin DA, Urdaneta F, Lobato EB. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2000;14(6):707-9. Available from: https://doi.org/10.1053/jcan.2000.18531
Jackson MR, Danby CA, Alving BM. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia. Ann Thorac Surg 1997;64:1815-7. Available from: https://doi.org/10.1016/s0003-4975(97)01065-5
Alvarez JM, Mezzatesta JP. Aprotinin and Organon 10172: a successful combination for coronary artery bypass surgery complicated by heparin-induced thrombocytopenia. Aust NZ J Surg 2000;70(11):819-21. Available from: https://doi.org/10.1046/j.1440-1622.2000.01959.x
Schmahl KS, Kanjoo AP, Harloff MG. Orgaran (Org 10172) for cardio-pulmonary by-pass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis. J Cardiothoracic Vasc Anesth 1997;11/2:262-264. Available from: https://doi.org/10.1016/s1053-0770(97)90239-1
Förster K, Kielstein J, Fleig S, Haller H, Schmidt H. Elimination of danaparoid (Orgaran) by use of HCO hemodialysis – a case report. 2011:Abstract MO359
Pillitteri D, Wegert W, Scholz T, Kirchmaier CM. Antidotal Effects of rFVIIa and FEIBA on Anticoagulant-Induced Inhibition of Thrombin Generation. Blood. 2006 Nov 16;108(11):4124.
Sarma, Anand & Ghoshal, Shivani & Craven, Spencer & Sarwal, Aarti. Intracerebral Hemorrhage: A Brief Evidence-Based Review of Common Etiologies, Mechanisms of Secondary Injury, and Medical and Surgical Management. Journal of Neuroanaesthesiol Crit Care 2019;6:119-130. 10.1055/s-0039-1689740.
Castelino RL, Maddula M, Tarafdar S, Sud K, Kairaitis L. Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing. Thromb Res 2019;180:70-73. Available from: https://dx.doi.org/10.1016/j.thromres.2019.06.008.
Bauersachs RM, Lindhoff-Last E, Klamroth R, Koster A, Schindewolf M, Magnani H. Danaparoid—Consensus Recommendations on Its Clinical Use. Pharmaceuticals, 2024,17(12):1584.
Suzuki N, Yoshioka N, Ohara T, Yokomichi N, Nako T, Yahagi N, et al. Risk factors for peri-operative venous thromboembolism: a retrospective study of Japanese women with gynecologic diseases. Thromb J 2010;8:17-25.Available from: https://doi.org/10.1186/1477-9560-8-17
Tani H, Itoh H, Kasaka K, Takemura M, Okada Y, Kawasaki K, et al. Prophylactic use of danaparoid sodium for deep vein thrombosis prophylaxis after Cesarian section. Adv Obstet Gynaecol 2005;57/3:309-10.
Nohira T, Kim S, Nakai H, Okabe K. Thromboembolic prophylaxis with danaparoid sodium for high thrombosis risk pregnant women after caesarian section. Jpn J Obstet Gynecol Neonatal Hematol 2004;13/2:5-11. Japanese.
Ito Y, Oka Y, Ikeda A. Investigation on safety and efficacy of danaparoid for prevention of venous thromboembolism after surgery for Gastrointestinal cancer. Ther Res 2005;26/6:1202-4.
Misaki T, Kitajima I, Kabata T, Tani M, Kabata C, Tsubokawa T, et al. Changes of the soluble fibrin monomer complex level during the peri-operative period of hip replacement surgery. J Orthop Sci 2008;13:319-24.
Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K. Heparin vs danaparoid for prevention of venous thromboembolism after hip surgery. J Orthoped Surg 2009;17/1:6-9. Available from: https://doi.org/10.1177/230949900901700102
Ten Cate H, Henny CP, Buller HR, Ten Cate JW, Magnani HN. Use of a heparinoid in patients with Haemorrhagic stroke and thromboembolic disease. Ann Neurol 1984;15:268-270. Available from: https://doi.org/10.1002/ana.410150311
Roth von B, Herkenrath P, Krebber J, Anschutz K. Use of a new heparinoid as the sole anticoagulant in haemodialysis of paediatric patient. Nieren- und Hochdrukkrankheiten. 1985;14/21:164.
Myllylahti, L., Pitkänen, H., Magnani, H., et al. Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. Thrombosis Journal 2022;20:4. Available from: https://doi.org/10.1186/s12959-021-00362-y.
Burkhard-Meier U, Sohngen D, Schultheiss H-P, Greinacher A, Schwartzkopff B, Vogt M, Heyll A, Schneider W. Heparin-induced thrombocytopenia Type-II: successful use of Orgaran (Org 10172) in intensive care patients. Inten Care Med 1995;21 552-4. Available from: https://doi.org/10.1007/bf01706210
Tardy-Poncet B, Tardy B, Reynaud J, Mahul P, Mismetti P, Mazet E, et al. Efficacy and safety of danaparoid sodium (Org 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999;115:1616-20. Available from: https://doi.org/10.1378/chest.115.6.1616
Henny ChP, Cate H ten, Cate JW ten, Surachno S, Bronswijk H van, Wilmink JM, et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983:i:890-3. Available from: https://doi.org/10.1016/s0140-6736(83)91326-0
Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer. 1986;58(3):761-4. Available from: https://doi.org/10.1002/1097-0142(19860801)58:3%3C761::aid-cncr2820580325%3E3.0.co;2-6
Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Portal vein thrombosis in liver cirrhosis. BMC Gastroenterol 2017;17:112-20.
Hayashi T, Takatori H, Horii R, Nio K, Tershima T, Lida N, et al. Danaparoid based anticoagulation therapy for portal vein thrombosis in cirrhotic patients. BMC Gastroenterol 2019;19:217.
Kawamura E, Enomoto M, Kotani K, Motoyama H, Kozuka R, Hagihara A, et al. Danaparoid sodium thrombolytic therapy followed by warfarin in cirrhotic portal venous thrombosis. Hepatol Internat 2016; 10/1 Suppl 1:S374.
Ohtake T, Tsuji K, Kawanishi T, Machida T, Takagi H, Mezawa S, et al. A multicentre survey of the efficacy and safety of danaparoid sodium treatment for portal vein thrombosis. Hepatology 2014;60/4 Suppl 1:399A Abstract 402.
Gindre I, Maistre E de, Perrin A, Lecompte T, Hoffman MA. Thrombopénies sous héparinothérapie. Utilisation du danaparoïde (Orgaran), trieze cas monocentriques sous le régime de l‘ATU. Thérapie 1997;52:591-7. French.
Sturtevant JM, Pillans PI, Mackenzie F, Gibbs HH. Heparin-induced thrombocytopenia: recent experience in a large teaching hospital. Int Med J 2006;36:431-6.
Fouroughinia F, Farsad F, Gholami K, Ahmadi S. Usefulness of danaparoid sodium in patients with heparin-induced thrombocytopenia after cardiac surgery. J Res Pharm Practice 2016;4/2:73-77.
Magnani HN, Wester JPJ. Is danaparoid anticoagulation suitable for patients with HIT and ARF requiring CVVRT? An analysis of case reports. Open Access Sci Reports 2012;1/9:1-7.
Begelman SM, Baghdaserian SB, Singh IM, Militello MA, Hursting MJ, Bartholomew J. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intens Care Med 2008;23/5:313-20. Available from: https://doi.org/10.1177/0885066608321246
Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intens Care Med 2006;21/2:86-92. Available from: https://doi.org/10.1177/0885066605284590
Saugel B, Phillip V, Moessmer G, Schmid RM, Huber W. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit Care 2010;14(3):R90. Available from: https://dx.doi.org/10.1186/cc9024.
Smythe MA, Koerber JM, Forsyth LL, Priziola JL, Balasubramaniam M, Mattson JC. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacother 2009;29:1073-81. Available from: https://doi.org/10.1592/phco.29.9.1073
Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel Y, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care 2015;19:396. Available from: https://dx.doi.org/10.1186/s13054-015-1109-0.
Vo QA, Lin JK, Tong LM. Efficacy and safety of argatroban and bivalirudin in patients with suspected heparin-induced thrombocytopenia. Ann Pharmacother. 2015;49(2):178-84. Available from: https://dx.doi.org/10.1177/1060028014562949.
Joseph L, Casanegra AI, Dhariwal M, Smith MA, Raju MG, Militello MA, et al. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia. Thromb Haemost. 2014;12(7):1044-53. Available from: https://dx.doi.org/10.1111/jth.12592.
Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006;26(4):452-60. Available from: https://dx.doi.org/10.1592/phco.26.4.452.
Pena de la Vega L, Miller RS, Benda MM,, et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 2005;80(8):995-1000. Available from: https://dx.doi.org/10.4065/80.8.995.
Carrier M, Rodger MA, Fergusson D, Doucette S, Kovacs MJ, Moore J, Kelton JG, Knoll GA. Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney International 2008;73:213–219. Available from: https://dx.doi.org/10.1038/sj.ki.5002631.
Mureebe L, Coats RD, Silliman WR, Shuster TA, Nichols WK, Silver D. Heparin-associated anti-platelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 2006;136(4):848-53. Available from: https://doi.org/10.1016/j.surg.2004.07.004
Ocak G, Vossen CY, Rotmans JI, Lijfering WM, Rosendaal FR, Parlevliet KJ, et al. Venous and arterial thrombosis in dialysis patients. Thromb Haemost 2011;106(6):1046-52. Available from: https://dx.doi.org/10.1160/TH11-06-0422.
Hoek JA, Henny CP, Knipscheer HC, ten Cate H, Nurmohamed MT, ten Cate JW. The effect of different anaesthetic techniques on the incidence of thrombosis following total hip replacement. Thromb Haemost 1991;65(2):122-5.
Leyvras P, Bachmann F, Bohnet J, Breyer HG, Estoppey D, Haas S, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine. Br J Surg 1992;79:911-4. Available from: https://doi.org/10.1002/bjs.1800790919
Comp PC, Voegeli T, McCutchen JW, Skoutakis VA, Trowbridge A, Overdyke WL. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement surgery: The danaparoid hip arthroplasty investigators group. Orthopedics 1998;21:1123-8. Available from: https://doi.org/10.3928/0147-7447-19981001-11
Roise O, Nurmohamed M, Reijnders P, Touzard R, Steikema J, Bachmann F, et al. A multicentre, randomised, assessor- blind, pilot study comparing the efficacy in the prophylaxis of DVT and the safety of Orgaran® (ORG 10172), Fragmin®, Clexane®/Lovenox® in patients undergoing surgery for a fractured hip. Thromb Haemost 1993;69(6):620 Abstr 273.
Merli GJ, Doyle L, Crabbe S, Sciarra A, Herbison G, Ditunno J. Prophylaxis for deep vein thrombosis in acute spinal cord injury comparing two doses of low molecular weight heparinoid in combination with external pneumatic compression. J Rehabil Res Dev 1991;28:434-5.
Barlingen HH van, Beek A van, Erkelens DW, Bruin TW de. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans. J Int Med 1997;242/2:125-9. Available from: https://doi.org/10.1046/j.1365-2796.1997.00157.x
Mikhailidis DP, Jagroop IA. Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans. J Int Med 1998;244/2:184.
Ireland H, Lane DA, Flynn A, Anastassiades E, Curtis JR. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Thromb Haemost 1986;55(02):271-5.
Von Bonsdorff M, Stiekema J, Harjanne A, Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. International J Artificial Organs 1990;13(2):103-8.
Frei U, Wilks MF, Boehmer S, Crisp-Lindgren N, Schwarzrock R, Stiekema JC, Koch KM. Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant. Nephrol Dial Transplant 1988;3(4):435-9. Available from: https://doi.org/10.1093/oxfordjournals.ndt.a091694
Charif R, Davenport A. Heparin‐induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapy. Hemodialysis International 2006;10(3):235-40. Available from: https://doi.org/10.1111/j.1542-4758.2006.00101.x
Finlay S, Price NJ, Crowther M, Bloomfield M. Acute HIT should be considered when cardio-respiratory arrest follows line insertion and/or heparin administration. Scottish Med J 2007;52/2:47-8.
Grandvuillemin A, Zanetta G, Perrin J, Amiral J, Elalamy I, de Maistre E. Unusual Case of HIT With Cardiac Arrest During Hemodialysis. Annals of Pharmacotherapy. 2014;48(8):1086-9. Available from: https://doi.org/10.1177/1060028014535361
Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12(12):2750-5. Available from: https://doi.org/10.1093/ndt/12.12.2750
Mims MP, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: A consequence of heparin‐induced thrombocytopenia. Europ J Haematol 2004;72(5):366-9. Available from: https://doi.org/10.1111/j.1600-0609.2004.00224.x
Neuhaus TJ, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediat Nephrol. 2000;14(8):713-6. Available from: https://doi.org/10.1007/pl00013423
Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane) and danaparoid sodium (Orgaran) in stable chronic haemodialysis patients. Am J Kidney Dis 2002;40/5:990-5.
Rostoker G, Senet P, Lepeytre F, Griuncelli M, Loridon C, Rabaté C,, et al. Analysis of liver iron concentration in an elderly female undergoing hemodialysis with calcific uremic arteriolopathy does not support the role of iron overload in calciphylaxis: lesson for the clinical nephrologist. J Nephrol 2021;34(5):1547-51. Available from: https://doi.org/10.1007/s40620-020-00904-z
Pont A-CJM de, Hofstra J-JH, Pik DR, Meijers JCM, Schulz MJ. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. Crit Care 2007;11:R10228,102.
Wester JPJ, Haas FJLM, Biesma DH, Leusink JA, Veth G. Thrombosis and haemorrhage in heparin-induced thrombocytopenia patients in seriously ill patients. Intens Care Med 2004;30:1927-34. Available from: https://doi.org/10.1007/s00134-004-2334-1
Magnani HN. Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders. In Xingshun Qi, Xiaozhong Guo, editors. Anticoagulation - Current P
Arangalage D, Lepage L, Faille D, Cimadevilla C, Dilly MP, Papy E,, et al. Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery. Eur J Cardio-Thoracic Surg 2016;50(6):1132-8. Available from: https://doi.org/10.1093/ejcts/ezw200
Mokni W, Khiem-el Aatmani AT, Thiranos JC, Koffel JC, Beretz L. Retrospective study of danaparoid sodium use in a French teaching hospital. J Pharmacie Clinique 2006;25(3):138-46.
Haouach K, Admou B, Lauriant P, Chabaa L. Contributions of biological tests and the 4 Ts score in the diagnosis of heparin induced thrombocytopenia. Pan African Medical Journal. 2012;13(1).
Piednoir P, Allou N, Provenchère S, Berroeta C, Huisse MG, Philip I, et al. Heparin-induced thrombocytopenia after cardiac surgery: an observational study of 1,722 patients. J Cardiothorac Vasc Anesthes 2012;26(4):585-90. Available from: https://doi.org/10.1053/j.jvca.2011.11.009
Tardy-Poncet B. French experience in the use of Orgaran as an alternative antithrombotic treatment for patients with heparin induced thrombocytopenia. Thromb Haemost 1997; Suppl:PS-1825a.
Tossios P, Krian A. Heparin-induced thrombocytopenia and associated complications after
Tauzi P, Aubourg C, Van SD, Gros A, Sargentini C, Rineau E. A Case Report of Pulmonary Embolectomy Under Cardiopulmonary Bypass in a Patient with Intracranial Hemorrhage and History of Heparin-Induced Thrombocytopenia. A&A Practice 2024;18(4):e01767.
Carrier M, Robitaille D, Perrault LP, Pellerin M, Page P, Cartier R., et al. Heparin versus danaparoid in off-pump coronary by-pass grafting: results of a prospective randomised clinical trial. J Thorac Cardiovasc Surg 2003;125/2:325-329. Available from: https://doi.org/10.1067/mtc.2003.103
Warkentin TE, Dunn GL, Cybulsky IJ. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia. Ann Thorac Surg 2001;72:1730-2. Available from: https://doi.org/10.1016/s0003-4975(01)02583-8
Mikić A, Velinović M, Vraneš M, Karan R, Savić N, Nikolić B., et al. Our experience in three coronary patients with heparin induced thrombocytopenia type II, platelets. J Cardiothorac Surg 2013;8 Suppl 1:P77. Available from: https://doi.org/10.1186/1749-8090-8-S1-P77
Barth KSA. Inzidenz der Heparin-induzierten Thrombozytopenie Typ II am Klinikum der Justus-Liebig-Universitaät Giessen. MD Thesis, Giessen 1998.
Bouallal R, Montaigne D, Fayad G, Auffray JL, Asseman P, Ennezat PV. Late bioprosthetic mitral valve thrombosis: a link with postoperative heparin-induced thrombocytopenia? J Am Soc Echocardiography 2009;22(11):1310-e5. Available from: https://doi.org/10.1016/j.echo.2009.06.007
Canaud L.. Danaparoid sodium/enoxaparin sodium. Reactions 2013;1467:13-31.
Chevalier J, Ducasse E, Dasnoy D, Puppinck P. Heparin-induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low-molecular-weight heparin. Eur J Vasc Endovasc Surg 2005;29(2):209-12. Available from: https://doi.org/10.1016/j.ejvs.2004.09.014
Collart F, Derouck D, Kerbaul F, Feier H, Mesana TG. Regression of intracardiac heparin-induced thrombosis after aortic root surgery. Ann Thoracic Surg 2003;76(2):617-9. Available from: https://doi.org/10.1016/s0003-4975(03)00161-9
Gitlin SD, Deeb M, Yann C, Schmaier AH. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 1998;27(3):568-75. Available from: https://doi.org/10.1016/s0741-5214(98)70336-2
Haas S. Fallbeispoele zur Therapie der HIT II aus gutachterlicher Sicht.Anaestheriol Intensivmed Notfallmed Schmertzther 2002;37 Suppl 1:S17-19. German.
Kollig E, Möllenhoff G, Wick M, Weber A, Muhr G. Wertigkeit der lokoregionalen Fibrinolyse von arteriellen Verschlüssen bei Heparin-induzierter Thrombozytopenie. Gefässchirurgie 1998;3(4):212-7. German.
Krenzien J, Gussmann A. Die Heparininduzierte Thrombopenie: Beobachtungen im eigenen Kranrengut. Zentralbl Chir 1999;124:230-3. German.
Kuhn B. Heparin-induzierte Thrombozytopenie- eine ernstzunehmende Komplikation im Rahmen einer Heparin Therapie. Unfallchirurg 1997;100:646-51. German.
Lam F, Hussein S, Li P. Case Reports: Limb loss following the use of heparin. J Bone Joint Surg 2001; 83-B: 588-9. Available from: https://doi.org/10.1302/0301-620x.84b4.11961
Morsdorf S, Pistorius C, Orthleb R, Pindur G, Schenk J. Late onset of heparin-induced thrombocytopenia with recurrent arterial thromboses and amputation. Dtsch med Wschr 1999;124(43): 1271-4. Available from: https://doi.org/10.1055/s-2007-1024531
Neuhaus TJ, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II in hemodialysis: switch to danaparoid. Pediatr Nephrol 2000;14(8):713-6. Available from: https://doi.org/10.1007/pl00013423
Pannicke N, Pollok JM, Kluge S, Petzoldt M. Heparin-induced thrombocytopenia associated with acute liver graft failure. Case Reports 2012;2012:bcr2012007323. Available from: https://doi.org/10.1136/bcr-2012-007323
Pfeiffer G, Eberhardt J, Hamann R. White Clot Syndrome bei heparin-induzierter thrombozytopenie Typ II mit Kreutzreaktion gegen danaparoid-Na (Orgaran). Gefaässchirurgie 2000;5(2):125-9. German.
Roullet S, Biais M, Stecken L, Laurent C, Neau-Cransac M, Sztark F. Thrombocytopenia and acute Budd–Chiari syndrome after liver transplantation: heparin-induced thrombocytopenia. B J Anaesthes 2011;107(3):475-7.
Warkentin TE, Pai M, Cook RJ. Intraoperative anticoagulation and limb amputations in patients with immune heparin‐induced thrombocytopenia who require vascular surgery. Thromb Haemost 2011;10:148-150. Available from: https://doi.org/10.1111/j.1538-7836.2011.04543.x
Golomb MR, Rafay M, Armstrong D, Massicotte P, Curtis R, Hune S., et al. Intra-arterial tissue plasminogen activator for thrombosis complicating cerebral angiography in a 17-year-old girl. J Child Neurology 2003;18(6):420-3. Available from: https://doi.org/10.1177/08830738030180060301
Muhm M, Claets L, Huk I, Koppensteiner R, Kyrle PA, Minar E., et al. Thrombo-embolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reaction to low molecular weight heparin – treatment with Org 10172(Lomoparan). Wien Klin Wochenschr 1997;109(4):128-131.
Oberst M, Vierling P, Thielemann F. Heparinassoziierte thrombopenie (HAT) Type II. Chirurg 1998;69:198-203. German
Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray B. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis. ANZ J Med 1991;21:52-4. Available from: https://doi.org/10.1111/j.1445-5994.1991.tb03003.x
Cantor WJ, Leblanc K, Garvey B, Watson KR, Rasymas A, Strauss BH. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin. Catheterization and Cardiovascular Interventions. 1999;46(3):352-5. Available from: https://doi.org/10.1002/(sici)1522-726x(199903)46:3%3C352::aid-ccd21%3E3.0.co;2-7
Pamboukian SV, Ignaszewski AP, Ross HJ. Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature. J Heart Lung Transplant 2000;19(8):810-4. Available from: https://doi.org/10.1016/s1053-2498(00)00133-9
Girisch M, Bheitel G, Ries M, Klinge J. Safe and effective use of danaparoid during cardiac catheterisation in a 14 month old boy with tetralogy of Fallot and heparin-induced thrombocytopenia. Ann Hematol 2001;80 Suppl: A20.
Ng T, Tillyer ML. Warfarin‐induced skin necrosis associated with Factor V Leiden and protein S deficiency. Clin Lab Haematol 2001;23(4):261-4. Available from: https://doi.org/10.1046/j.1365-2257.2001.00399.x
Morikawa M, Yamada H, Kato EH, Wada S, Suzuki S, Sakuragi N, et al. Failure of thromboprophylaxis in pregnancy caused by dual deficiencies of Protein S and Protein C. Semin Thromb Hemost 2005;31/3:261-4. Available from: https://doi.org/10.1055/s-2005-872429
Rammos S, Apostolopoulou SC, Laskari C, Kiaffas M, Kyrvassilis G, Sofianidou I., et al. Transcatheter Closure of Secundum Atrial Septal Defect Using the Amplatzer Device: Single Center Experience in 140 Patients. Hospital Chronicles 2008;3(1):38-44.
Bentaarit B, Duval AM, Maraval A, Dahmane D, Dahan K, Amara B, et al. Paradoxical embolism following thromboaspiration of an arteriovenous fistula thrombosis: a case report. J Med Case Reports. 2010;4(1):345. Available from: https://doi.org/10.1186/1752-1947-4-345
Milnik A, Roggenbuck D, Conrad K, Bartels C. Acute inflammatory neuropathy with monoclonal anti-GM2 IgM antibodies, IgM-κ paraprotein and additional autoimmune processes in association with a diffuse large B-cell non-Hodgkin's lymphoma. Case Reports 2013;2013:bcr1120115087. Available from: https://doi.org/10.1136/bcr-11-2011-5087
Leroux L, Seguy B, Labrousse L, Casassus F, Dijos M, Dos-Santos P., et al. How should I treat a cardiac arrest during transcatheter aortic valve implantation? EuroIntervention 2014;10(5):648-50. Available from: https://doi.org/10.4244/eijv10i5a112
Bauer C, Vichova Z, Ffrench P, Hercule C, Jegaden O, Bastien O., et al. Extracorporeal membrane oxygenation with danaparoid sodium after massive pulmonary embolism. Anesthes Analg 2008;106(4):1101-3. Available from: https://doi.org/10.1213/ane.0b013e31816794d9
Benke S, Moltzan C. Co‐existence of heparin‐induced thrombocytopenia and thrombotic thrombocytopenic purpura in a postoperative cardiac surgery patient. Am J Hematol 2005;80(4):288-91. Available from: https://doi.org/10.1002/ajh.20436
Betz C, Kraus D, Müller C, Geiger H. Iliac cuffed tunnelled catheters for chronic haemodialysis vascular access. Nephrol Dial Transplant 2006;21(7):2009-12.
Boon DMS, Michiels JJ, Tanghe HLJ, Kappes-Klunne MC. Heparin-induced thrombocytopenia with multiple cerebral infarctions simulating thrombotic thrombocytopenic purpura. Angiology 1996;47(4):407-11. Available from: https://doi.org/10.1177/000331979604700413
Bremaud M, De Maistre E, Junke E, Guerci A, Lalot JM, Longrois D., et al. Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia. Ann Fr Anesth Reanim 2004; 23(1): 50-5. Available from: https://doi.org/10.1016/j.annfar.2003.10.009
Buerger T, Tautenhahn J, Meyer F, Lippert H. Heparin-induced vascular occlusion in vasculo-surgical patients- an evaluation of the disease in 13 patients. J Cardiovasc Surg 1999; 40(2): 237-42.
Ducloy-Bouthors A-S, Trillot N, Depret T, Provost-Helou N, Ennezat P-V, Fleyfel M., et al. Conduite a tenir diagnostique devant une thrombopenie chez une patiente sous heparine pendent la grossesse, l’accouchement ou le post partum: a propos de 4 cas. 2006 pre-print. French.
Emig U, Meyer T, Buchwald AB. Erfolgreiche lysetherapie einer Vena-cava Inferior and Iliofemoral Venenthrombose bei Heparin-induzierte Thrombozytopenie Typ II. Dtsch med Wschr 1997;122:965-8. German.
Fernandes P, Mayer R, MacDonald JL, Cleland, AG, Hay-McKay C. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases. Perfusion 2000;15(6):531-9. Available from: https://doi.org/10.1177/026765910001500610
Helbig D, Hillen U, Grabbe S, Dissemond J. Skin and mucosal ulcerations in heparin-induced thrombocytopenia (HIT) II. Hautarzt 2007;58(9):774-780. Available from: https://doi.org/10.1007/s00105-007-1300-6
Langenfeld H. Heparin-induzierte Thrombopenie - Ein fast fataler Verlauf bei einem Patienten. Anasthesiol Intensivmed 2000; 41: 542-4. German.
Wajon P, Beehan S. Hirudin anticoagulation for CPB. Anaesth Intens Care 2002;30(5):700.
Zohrer B, Zenz W, Rettenbacher A., et al. Danaparoid sodium (Orgaran®) in four children with heparin induced thrombocytopenia type II. Acta Paediatrica 2001;90:765-71.
Mallios A, Jennings W. White clot syndrome. Eur J Vasc Endovasc Surg 2018;55:404. Available from: https://doi.org/10.1016/j.ejvs.2017.09.007
Eustatia-Rutten CF, van Baalen JM, Kamper AM. Severe Inflammation of a PTFE Shunt due to Topical Heparin Administration. EJVES Extra 2001;1(5):77-8.
Magnani HN, Gallus A. Heparin induced thrombocytopenia: A report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran®) from 1982 to mid-2004. Thromb Haemost 2006;95/6:967-81.
Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-7.
Warkentin TE. Danaparoid (Orgaran®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in- vitro thrombin and cross-linked fibrin generation and evaluation if the clinical significance of in-vitro cross reactivity (XR) of danaparoid for HIT IgG. Blood 1996;88(1):626A Abstr 2493.
Gerotziafas GT, Samama MM, Elalamy I. Heparin-induced thrombocytopenia: Pathogenesis, epidemiology, diagnosis and management. Haematol 2004;7/1:22-34.
Wenz B, Burns ER. Rapid removal of heparin from plasma by affinity filtration. Am J Clin Path 1991 Sep;96(3):385-90. Available from: https://dx.doi.org/10.1093/ajcp/96.3.385.
Potzsch B, Keller M, Madlener K, Muller-Berghaus G. The use of heparinase improves the specificity of cross-reactivity testing in heparin-induced thrombocytopenia. Thromb. Haemost 1996;76:1121.
White MM, Siders L, Jennings LK, White FL. The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia. Thromb Haemost 1992 Jul 6;68(1):88.
Morel-Kopp MC, Mullier F, Gkalea V, Bakchoul T, Minet V, Elalamy I., et al. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: Communication from the SSC of the ISTH. Thromb Haemost 2016;14:2548–2552. Available from: https://dx.doi.org/10.1111/jth.13516.
Minet V, Dogné JM, Mullier F. Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. Molecules. 2017 Apr 11;22(4):617. Available from: https://dx.doi.org/10.3390/molecules22040617.
Bansai V, Mazariegos M, Grewal A, Bajwa J, Bontekoe E, Hoppenstaedt D, Iqbal O, Fareed J. Persistence of circulating residual heparin in ESRD patients undergoing maintenance hemodialysis. Nephrol Dial Transplant 2020;35 Suppl 3:P1077. Available from: https://doi.org/10.1093/ndt/gfaa142.P1077.
Kanack AJ, Athale J, Leger RR, Saadalla A, Heikal NM, Chen D., et al. Autoimmune HIT antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes. Blood Adv. 2023;7/16:4431-4434. Available from: https://doi.org/10.1182/bloodadvances.2023009811
Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol. 1998;35(4) Suppl 5:17-25 & 35-6.
Greinacher A and Warkentin TW. Treatment of heparin-induced thrombocytopenia: an overview. In Warkentin TE, Greinacher A editors. Heparin-Induced thrombocytopenia. Boca Raton: CRC Press‐Taylor and Francis Group. 5th ed 2013. p. 315-355.
Chong BH. Heparin-induced thrombocytopenia. Thromb Haemost 2003;1(7):1471-8.
Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y., et al. American Society of Hematology 2018 guidelines for management of venous thrombosis: heparin-induced thrombocytopenia. Blood Advances 2018;22(2):3360-3392. Available from: https://doi.org/10.1002/14651858.cd013399.pub2
Gruel Y, De Maistre E, Pouplard C, Susen S, Roullet S, Albaladejo P., et al. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth Crit Care Pain Med 2020;39:291-310
Elalamy I, Tardy-Poncet B, Mulot A, Maistre E de, Pouplard C, Nguyen P, et al. Risk factors for unfavourable clinical outcome in patients with documented heparin-induced thrombocytopenia. Thromb Res 2009;124:554-9. Available from: https://doi.org/10.1016/j.thromres.2009.04.002
Kodityal S, Manhas AH, Udden M, Rice L.. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol 2003;71(2):109-13.
Trojan M, Ihbe-Heffinger A, Greinacher A, Unkrig C, Müller A, Bernard R, Querbach C. GRP-095 Improving Medication Safety: The Danaparoid Story. Eur J Hosp Pharm 2013;20 Suppl 1:A34-5.
Tardy-Poncet B, Tardy B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins must be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999;82:1199-200.
Muzzafar TH. Forgotten source of heparin as a cause of worsening platelet count in a pre-existing heparin-induced thrombocytopenia. Iranian Red Crescent Med J 2008;10/4:335-337.
Farkh C, Wicky PH, Perrier-Cornet A, Koskas M, Ajzenberg N, Faille D. Danaparoid failure in heparin-induced thrombocytopenia due to acquired antithrombin deficiency: A case report. Thromb Res 2025;247:109280. Available from: https://doi.org/10.1016/j.thromres.2025.109280
Warkentin TE. Think of HIT. Hematology 2006;1:406-414.
Pickert SM, Gathof BS. Die heparininduzierte Thrombozytopenie. Der Orthopäde. 2004;33(11):1300-8. German. Available from: https://doi.org/10.1007/s00132-004-0695-3
Charif R, Davenport A. Heparin‐induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapy. Hemodialysis International 2006;10(3):235-40. Available from: https://doi.org/10.1111/j.1542-4758.2006.00101.x
Finlay S, Price NJ, Crowther M, Bloomfield M. Acute HIT should be considered when cardio-respiratory arrest follows line insertion and/or heparin administration. Scottish Med J 2007;52/2:47-8.
Grandvuillemin A, Zanetta G, Perrin J, Amiral J, Elalamy I, de Maistre E. Unusual Case of HIT With Cardiac Arrest During Hemodialysis. Annals of Pharmacotherapy. 2014;48(8):1086-9. Available from: https://doi.org/10.1177/1060028014535361
Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12(12):2750-5. Available from: https://doi.org/10.1093/ndt/12.12.2750
Mims MP, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: A consequence of heparin‐induced thrombocytopenia. Europ J Haematol 2004;72(5):366-9. Available from: https://doi.org/10.1111/j.1600-0609.2004.00224.x
Neuhaus TJ, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediat Nephrol. 2000;14(8):713-6.
Selleng K, Selleng S, Raschke R, Schmidt CO, Rosenblood GS, Greinacher A, Warkentin TE. Immune heparin‐induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. Am J Hematol 2005;78(3):188-92. Available from: https://doi.org/10.1002/ajh.20305
Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121(7):632-6. Available from: https://doi.org/10.1016/j.amjmed.2008.03.012
Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opinion on Drug Safety 2009;8(2):129-44. Available from: https://doi.org/10.1517/14740330902778180
Warkentin TE. Immunologic effects of heparin associated with hemodialysis: Focus on heparin-induced thrombocytopenia. Semin Nephrol 2023;43(6):151479). Available from: https://doi.org/10.1016/j.semnephrol.2023.151479
Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004;34/12:1916-8. Available from: https://doi.org/10.1111/j.1365-2222.2004.02129.x
Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12:2750-5. Available from: https://doi.org/10.1093/ndt/12.12.2750
Boer WH, Liem Y, de Beus E, Abrahams AC. Acute reactions to polysulfone/polyethersulfone dialysers: a literature review and management. Ned J Med 2017;75/1:4-12.
Davenport A. Pyrexia of unknown origin. Nephrol Dial Transplant 2008;2:109-11.
Schindwolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, et al. Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia. J Thromb Haemost. 2010;8(7):1486-1491. Available from: https://doi.org/10.1111/j.1538-7836.2010.03795.x
Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis 2002;46:29-32. Available from: https://doi.org/10.1034/j.1600-0536.2002.460106.x
Boehncke WH, Weber L, Gall H. Toleranz gegenüber Intravenöser Applikation von Heparin und Heparinoid bei einer Patientin mit Typ-IV Allergie auf Heparine und Heparinoide. Allergologie 1996;19:95.
Liew G, Campbell C Thursby P. Delayed type hypersensitivity to subcutaneous heparin with tolerance to i.v. administration. ANZ J Surg 2004;74/11:1020-1021.
Gaigl Z, Klein CE, Grossmann R, Pfeuffer P, Raith P, Bröcker EB, et al. Managing allergy to heparins. Dtsch Arztebl 2006;103/43:A 2877-81.
Figarella I, Barbaud A, Lecompte T, De Maistre D, Reichert-Penetrat S, Schmutz JL. Reaction cutanee d’hypersensibilite retardee avec polysensibilisation aux heparines et heparinoides. Ann Dermatol Venereol 2001;128:25-30. French.
Rauova L, Arepally G, Poncz M, Cines DB. Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT). Autoimmun Rev. 2018 Oct;17(10):1046-1052. Available from: https://dx.doi.org/10.1016/j.autrev.2018.05.003.
Bergqvist D, Kettunen K, Fredin H, Fauno P, Suomalainen O, Soimakallio S, et al. Thromboprophylaxis in hip fracture patients – a prospective randomised comparative study between Org 10172 and dextran 70. Surgery 1991;109:612-622.
Gerhart T, Yett HS, Robertson L, Lee MA, Smith M, Salzman E. Low molecular weight heparinoid compared with heparin for prophylaxis of deep vein thrombosis in patients who are operated on for fractures of the hip. J Bone Joint Surg 1991;73A:494-502.
Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective Surgery for malignant disease? A double-blind randomised multicentre comparison, Throm Haemost 1993;70(4):562-567.
Warkentin TE. Heparin-Induced Thrombocytopenia. In Kitchens CS, Kessler CM, Konkle BA editors. Consultative Hemostasis and Thrombosis. W.B. Saunders 2013. p. 442-473. Available from: https://doi.org/10.1016/B978-1-4557-2296-9.00025-7.
Warkentin TE, Kelton JG. Delayed onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502-506.
Jackson MR, Neilson WJ, lary M, Baay P, web K, Clagett GP. Delayed-onset heparin-induced thrombocytopenia and thrombosis after intraoperative heparin anticoagulation: four case reports. Vasc Endovasc Surg 2006;40:67–70. Available from: https://dx.doi.org/10.1177/153857440604000109.
Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. Thromb Haemost 2017;15(11):2099-2114. Available from: https://dx.doi.org/10.1111/jth.13813.
Jaax ME, Krauel K, Marschall T, Brandt S, Gansler J, Furll BF, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 2013;122:272-281. Available from: https://dx.doi.org/10.1182/blood-2013-01-478966.
Risi G. Characterisation of PF4-danaparoid complexes by Photon correlation spectroscopy and Zeta potential. Ronzoni report 2016 (on file Veratis).
Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani HN. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia for patients receiving danaparoid, ancrod and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006;117:507-515.
Schenk JF, Pindur G, Stephan B, Mörsdorf S, Mertzlufft F, Kroll H, et al. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran®) in patients with heparin-induced thrombocytopenia. Clin Applied Thromb/Hemost 2003;9(1):25-32.
Cuker A. Management of multiple phases of heparin-induced thrombocytopenia. Thromb Haemost 2016;116:835-842. Available from: https://doi.org/10.1160/th16-02-0084
Bankova A, Andres Y, Horn MP, Alberio L, Nagler M. Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice. PLoS One 2017;12(6):e0178289. Available from: https://dx.doi.org/10.1371/journal.pone.0178289.
Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. J Clin Med 2020; 9(4):1226. https://doi.org/10.3390/jcm9041226.
Harenberg J, Zimmermann R, Schwartz F, Kübler W. Treatment of heparin-induced thrombocytopenia with thrombosis by a new heparinoid. Lancet 1983;30:986-7.
Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, et al. Prospective open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 2001;86:1170-5.
Farner B, Eichler P, Kroll H, Greinacher A. A comparison of lepirudin and danaparoid in patients with heparin-induced thrombocytopenia (HIT). Thromb Haemost 2001;85:950-7.
Schröder A, Scherlitzky L, Budde U, Imig H. Recent aspects in the diagnosis and therapy of heparin-induced thrombocytopenia Type II with thrombosis or haemorrhagic complications. Zentralbl Chir 1994;119 Suppl 1:151-3.
Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux versus argatroban and danaparoid for the treatment of suspected or confirmed heparin-induced thrombocytopenia: A prospective score analysis. Am Soc Hematol (ASH) Blood 2012;120:2262.
Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications; meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and it as therapeutic APTT range. Blood 2000; 96:846-851.
Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. For the ARG-911 study investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843. Available from: https://doi.org/10.1161/01.cir.103.14.1838
Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. For the ARG-915 investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856.
Wada H, Honda G, Kawano N, Uchiyama T, Kawasugi K, Madoiwa S, et al. Severe antithrombin deficiency may be associated with a high risk of pathological progression of DIC with suppressed fibrinolysis. Clin Applied Thromb/Hemost. 2020;26:1076029620941112. Available from: https://doi.org/10.1177/1076029620941112
Kushimoto S, Wada H, Kawasugi K, Okamoto K, Uchiyama T, Seki Y, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Increased ratio of soluble fibrin formation/thrombin generation in patients with DIC. Clin Applied Thromb/Hemost 2012;18(6):628-32. Available from: https://doi.org/10.1177/1076029612451648
Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. Thromb Haemost 2016;14:518–30.
Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nature Reviews Disease Primers 2016;2:16037.
Inata, Y. Should we treat sepsis-induced DIC with anticoagulants?. Intensive Care 2020;8:18-20. Available from: https://doi.org/10.1186/s40560-020-0435-8.
Krupiczojc MA, Scotton CJ, Chambers RC. Coagulation signalling following tissue injury: focus on the role of factor Xa. Int J Bioch Cell biol 2008;40(6-7):1228-37. Available from: https://doi.org/10.1016/j.biocel.2008.02.026
Yamakawa K, Umemura Y, Hayakawa M, Kudo D, Sanui M, Takahashi H, et al. Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20(1):229. Available from: https://dx.doi.org/10.1186/s13054-016-1415-1.
Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. Thromb Haemost 2015;13/4:671-675.
Asakura H. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease. Int J Hematol 2025;121:586-591.
Iba T, Gando S, Saitoh D, Wada H, Di Nisio M, Thachil J. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2016;145:46-50.
Iba T, Levy JH, Raj A, Warkentin TE. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Clin Med. 2019;22;8(5):728.
Seki Y, Okamoto K, Ikezoe T, Yamakawa K, Madoiwa S, Uchiyama T, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: Part 3 solid cancers and vascular abnormalities. Int J Hematol 2025;121:622-632. Available from: https://doi.org/10.1007/s12185-024-03912-y
Miyake Y, Yokota K, Fujishima Y, Sukamoto T. The effects of danaparoid, dalteparin and heparin on tissue factor induced experimental disseminated intravascular coagulation and bleeding time in the rat. Blood Coagul Fibrinolysis 2001;12/5:349-57. Available from: https://doi.org/10.1097/00001721-200107000-00003
Fujishima Y, Yokota K, Sukamoto T. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. Thromb Res 1998;91:221-227. Available from: https://doi.org/10.1016/s0049-3848(98)00094-2
Iba T, Myaho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxaemic rats. Crit Care 2008;12/4:1-7.
Hagiwara S, Iwasaka H, Uchida T, Hasegawa A, Asai N, Noguchi T. Danaparoid prevents cerulein-induced pancreatitis in rats. Shock 2009;32/1:94-99. Available from: https://doi.org/10.1097/shk.0b013e31818ec2c2
Shimosawa M, Sakamoto K, Tomari Y, Kamikado K, Otsuka H, Liu N, et al. Lipopolysaccharide-triggered acute aggravation of mesangioproliferative glomerulonephritis through activation of coagulation in a high IgA strain of ddY mice. Nephron Experimental Nephrology. 2009 ;112(4):e81-91. Available from: https://doi.org/10.1159/000224798
Hagiwara S, Iwasaka H, Shingu C, Matsumoto S, Uchida T, Nishida T, et al. Danaparoid sodium attenuates the effects of heat stress. J Surg Res 2011;171:762-8. Available from: https://doi.org/10.1016/j.jss.2010.05.008
Hino H, Miura A, Shin M, Kon W, Tateda T. Administration of Antithrombin in conjunction with danaparoid improves nerve conduction deterioration in the peripheral nerves of rats administered with LPS over a period of 48 hrs. Anesth Analg 2011;112 S-97.
Hino H, Miura A, Shinmi S, Inoue S. 1417: Prevention of glycocalyx degradation on sciatic nerves by danaparoid in a septic rat model. Crit Care Med. 2016;44(12):430.
Lu X, Zhao L, Xu YH. Low molecular weight heparin (danaparoid sodium) prevents CLP-induced acute lung injury in rats by anti-inflammatory coagulation. Bosn J Basic Med Sc 2013;13/1:50-56. Available from: https://doi.org/10.17305/bjbms.2013.2419
Iba T, Kidokoro A, Fukunaga M, Nagakari K, Suda M, Yoshikawa S, et al. Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med 2005;31:1101-8. Available from: https://doi.org/10.1007/s00134-005-2707-0
Takabuchi H, Tsuji H, Yoneda M, Takada O, Watanabe M, Uno M, et al. Anticoagulant profile of low molecular weight heparinoid (KB-101) and it’s in vivo effects on experimental DIC. Jpn J Thromb Haemost 1992;3:169-177. Japanese.
Nakahara M, Yasuda T, Taniguchi J, Kakihama Y, Kanmura Y. Efficacy of danaparoid on sepsis with DIC in patients admitted to the ICU. Proc. Am. Soc. Anesthesiol, 2009, A913.
Ikeda K, Ikeda H, Taniuchi H, Ueno T, Sada S. The effect of danaparoid sodium combined with antithrombin for patients with systemic inflammatory response syndrome (SIRS) associated with coagulopathy (SAC). Intens Care Med 2008; 21st ESICM Ann Congress Lisbon 2008:S266 Abstract 1043.
Kanbayashi J-I, Mochizuki H, Shiba T, Takeda S. Clinical evaluation of KB-101 (danaparoid sodium) against DIC in surgically severe infectious disease. J Clin Ther Med 1995;11/6:1227-43.
Iba T, Kidokoro A. Disseminated intravascular coagulation. Nippon Rinsho 2003;61/6:1010-4. Japanese.
Yoshika M, Komiyama Y, Hirakawa A, Nakatani T, Takahashi H. A difficult case of prolonged thrombocytopenia with sepsis and disseminated intravascular coagulation. Clin Appl Thromb Hemost 2011;17/4:410-3.
Ogawa A, Niwa H, Ogawa Y. A case of chronic DIC for which danaparoid was effective. Medicine and Drug J 2003;39/1:168-171.
Yagi T, Nakamura H, Wakamatsu T, Imura Y, Tamiya H, Sabe H, et al. Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self‑subcutaneous unfractionated heparin calcium injection: A case report. Mol Clin Oncol 2021;14/5:104-9. ePub. Available from: https://doi.org/10.3892/mco.2021.2266.
Minakata D, Fujiwara SI, Hayakawa J, Nakasone H, Ikeda T, Kawaguchi SI, et al. Comparison of danaparoid sodium and synthetic protease inhibitors for the treatment of disseminated intravascular coagulation associated with hematological malignancies: a retrospective analysis. Acta Haematologica 2020 143(3), 250-259. Available from: https://doi.org/10.1159/000501818.
Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S. Kasabach-Merritt syndrome associated with giant liver haemangioma: the effect of combined therapy with danaparoid and tranexamic acid. Haematologica 2005 ;90 Suppl: ECR29-ECR29,E-case.
Imafuku S, Hosokawa C, Moroi Y, Furue M. Kasabach-Merritt syndrome associated with angiosarcoma of the scalp successfully treated with chemoradiotherapy. Acta Dermatol-Venereol 2007;88/2:193-4. Available from: https://doi.org/10.2340/00015555-0378
Moriguchi A, Iwahashi K, Onishi Y, Kita H, Nishio A, Kanno T, et al. An operated case of retroperitoneal venous hemangioma complicated with Kasabach-Merritt syndrome which was well controlled by danaparoid sodium. Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 2009;106/11:1660-8. (Japanese).
Ebina Y, Hazama R, Nishimoto M, Tanimura K, et al. Resection of giant liver hemangioma in a pregnant woman with coagulopathy: case report and literature review. J Prenatal Med 2011;5:93-6.
Ontachi Y, Asakura H, Arahata M, Kadohira Y, Maekawa M, Hayashi T, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circulation J 2005 ;69 :1150-3. Available from: https://doi.org/10.1253/circj.69.1150
Yamada S, Asakura H. Therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm. Int J Mol Sci 2022;23:1296-1317. Available from: https://doi.org/10.3390/ijms23031296
Hijikata Y, Suda T, Nakagawa Y, Makuuchi Y, Ota Y, Tachibana S, et al. A case of gastrectomy for gastric cancer complicated with chronic disseminated intravascular coagulation syndrome associated with aortic aneurysm. J Tokyo Med Uni 2019;77/2:154-159. Japanese.
Kimura S-I, Odawara J, Aoki T, Yakamura M, Takeuchi M, Watanabe Y, et al. Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure. Int J Hematol 2009;89:549-52. Available from: https://doi.org/10.1007/s12185-009-0309-2
Akashi O, Kanemura S, Kobayashi K, Suto Y, Tazikawa K, Osawa H, et al. Danaparoid sodium controlled chronic disseminated intravascular coagulation associated with chronic aortic dissection and patent false lumen for a long term. Report of a case. Jpn J Thoracic Surg 2021;74:701-704. Japanese.
Koseki M, Asada N, Uryu H., et al. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol 2007;86:403–406. Available from: https://dx.doi.org/10.1007/BF02983996
Habe K, Wada H, Ito-Habe N, Suzuki H, Nobori T, Mizutani H. Two patients with antiphospholipid syndrome developed disseminated intravascular coagulation. Intern Med 2013;52:269-72.
Hyo Y, Fujisaki T, Hyo R, Tanaka H, Harada T. Iliopsoas abscess possibly due to Klebsiella pneumoniae infection after radiotherapy for hypopharyngeal cancer. Case Rpts Otolaryngol 2016;article ID 1343106. Available from: https://doi.org/10.1155/2016/1343106
Morizono S, Enjoji M, Sonoda N, Fukushima M, Kuniyoshi M, Kotoh K, et al. Lemierre’s syndrome: Porphyromonas asaccharolytica as a putative pathogen. Int Med 2005;44/4:350-3. Available from: https://doi.org/10.2169/internalmedicine.44.350
Yabuki T, Takeyama N, Aoki R, Noguchi H, Inoue Y, Nakagawa T, et al. Septic patient with thrombocytopenia and symmetrical peripheral gangrene associated with decreased ADAMTS13 activity. JJAAM 2007;18:775-80. Japanese.
Eguchi Y. Efficacy of recombinant thrombomodulin in septic disseminated intravascular coagulation refractory to antithrombin concentrate analysed by molecular markers. Thromb Haemost 2011;9 Suppl 2:427 Abstract P-TU-376.
Nakahara M, Yasuda T, Ikoma K, Daiguuji A, Kikuchi T, Kakihana Y. Efficacy of recombinant soluble thrombomodulin in disseminated intravascular coagulation associated with sepsis. Eur J Anaesthesiol 2011;28:177.
Umegaki T, Nishi K, Hatano K, Akamoto A, Hamano N, Yamazaki E, et al. Effects of human recombinant thrombomodulin and danaparoid sodium for sepsis-induced disseminated intravascular coagulation. J Jpn Soc Intens Care Med 2012;19:603-8. Japanese.
Eguchi Y, Gando S, Ishikura H, Saitoh D, Mimuro J, Takahashi H, et al. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intens Care. 2014;2:1-0. Available from: https://doi.org/10.1186/2052-0492-2-30
Kawasugi K, Wada H, Honda G, Kawano N, Uchiyama T, Madoiwa S, et al. Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. Thrombosis Journal. 2021;19:1-7. Available from: https://doi.org/10.1186/s12959-021-00264-z
Ohbe H, Isogai S, Jo T, Matsui H, Fushimi K, Yasunaga H. Treatment with Antithrombin or Thrombomodulin and Mortality from Heatstroke-Induced Disseminated Intravascular Coagulation: A Nationwide Observational Study. Semin Thromb Hemost 2019; 45(08): 760-766. Available from: HTTPS://DX.DOI.ORG/10.1055/s-0039-1700520.
Suetani K, Okuse K, Nakahara K, Michikawa Y, Noguchi Y, Suzuki M, et al. Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation. World J Gastroenterol 2015;21/2:533-40. Available from: https://doi.org/10.3748/wjg.v21.i2.533
Suzuki J, Sasabuchi Y, Hatakeyama S, Matsui H, Sasahara T, Morisawa Y, et al. The effect of antithrombin added to recombinant human-soluble thrombomodulin for severe community-acquired pneumonia-associated disseminated intravascular coagulation: a retrospective cohort study using a nationwide inpatient database. Intens Care 2020;8:8. Available from: https://dx.doi.org/10.1186/s40560-019-0419-8.
Ito T, Nagahara A, Osada T, Kato J, Ueyama H, Saito H, et al.. Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field. Biomed Reports 2015;3(4):457-60.
Kato Y, Kawaguchi H, Iwataki S, Kihara H, Okada S. Recombinant human soluble thrombomodulin and danaparoid combination anticoagulation therapy for disseminated vascular coagulation in a child with streptococcal toxic shock syndrome: A case report. Experiment Therapeut Med 2022;24:714-9. Available from: https://doi.org/10.3892/etm.2022.11650
Fujita M, Abe K, Hayashi M, Okai K, Takahashi A, Ohira H. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization. Fukushima J Med Sci 2017; 63(3):165-171 (Japanese).
Umegaki T, Nishi K, Hatano K, Akamoto A, Hamano N, Yamazaki E, et al. Effects of human recombinant thrombomodulin and danaparoid sodium for sepsis-induced disseminated intravascular coagulation. J Jpn So